Background and Purpose-Granulocyte-colony stimulating factor (G-CSF) is neuroprotective in experimental stroke and mobilizes CD34 ϩ peripheral blood stem cells into the circulation. We assessed the safety of G-CSF in recent stroke in a phase IIb single-center randomized, controlled trial. Methods-G-CSF (10 g/kg) or placebo (ratio 2:1) was given SC for 5 days to 60 patients 3 to 30 days after ischemic or hemorrhagic stroke. The primary outcome was the frequency of serious adverse events. Peripheral blood counts, CD34 ϩ count, and functional outcome were measured. MRI assessed lesion volume, atrophy, and the presence of iron-labeled CD34 ϩ cells reinjected on day 6. Results-Sixty patients were recruited at mean of 8 days (SD Ϯ5) post ictus, with mean age 71 years (Ϯ12 years) and 53% men. The groups were well matched for baseline minimization/prognostic factors. There were no significant differences between groups in the number of participants with serious adverse events: G-CSF 15 (37.5%) of 40 versus placebo 7 (35%) of 20, death or dependency (modified Rankin Score: G-CSF 3.3Ϯ1.3, placebo 3.0Ϯ1.3) at 90 days, or the number of injections received. G-CSF increased CD34 ϩ and total white cell counts of 9.5-and 4.2-fold, respectively. There was a trend toward reduction in MRI ischemic lesion volume with respect to change from baseline in G-CSF-treated patients (Pϭ0.06). In 1 participant, there was suggestion that labeled CD34 ϩ cells had migrated to the ischemic lesion. 
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Key Words: granulocyte colony-stimulating factor Ⅲ stroke recovery Ⅲ CD34 Ⅲ hematopoietic stem cell F ew interventions aid recovery for patients with acute stroke, and although earlier trials of putative neuroprotectants failed (eg, NXY-059 1 ), new studies are ongoing, including focusing on colony-stimulating factors, such as granulocyte-colony stimulating factor (G-CSF) and erythropoietin, where promising data exist for preclinical experimental models of stroke. 2 G-CSF is a glycoprotein hormone encoded by a single gene located on chromosome 17 q11-22 3 ; it plays a key role in the regulation of granulopoiesis and is responsible for the terminal maturation of neutrophils. Recombinant G-CSF is used for treatment of neutropenia and for production of CD34 ϩ hematopoietic stem cells (HSCs)
for bone marrow transplantation. When considering G-CSF as a potential treatment for stroke, the mechanisms of action appear to be multimodal. Experimentally, neuroprotection occurs by reducing apoptosis in the ischemic penumbra and attenuating the inflammatory cascade. 4 It also appears to be neuroreparative through potentiating angiogenesis 5 and neurogenesis, 4 in part by activating brain endothelial cells 6 and mobilizing HSCs to migrate to the ischemic lesion. 7 More contentiously, bone marrow-derived stem cells have been shown to differentiate into neurons and glia, 8 and experimental transplants of HSCs have been observed to improve outcome post stroke. 9 The purpose of the present trial, Stem
Cell Trial of Recovery Enhancement After Stroke 2, was to further evaluate the safety of G-CSF in stroke with emphasis on its effects on bone marrow-derived HSCs and their fate in the brain.
Methods

Design
We performed a prospective, single-center, double-blind, randomized, placebo-controlled, phase IIb trial of G-CSF in patients with subacute stroke. 
Intervention
Participants were randomly assigned 2:1 to receive subcutaneous human recombinant G-CSF (1ϫ10 6 units/kg, equivalent to 10 g/kg, Neupogen, Amgen, the maximum dose in Stem Cell Trial of Recovery Enhancement After Stroke 1 10 ) or matching subcutaneous saline once per day for 5 days. Treatment was prepared centrally and both the participants and those administering the injections were blinded to treatment and its assignment. Randomization involved computerized minimization (online-only Supplemental Table 1 ), and randomized treatment was administered in addition to best medical care.
Clinical Outcomes
The primary outcome measure was safety assessed as the number of participants having a serious adverse event (SAE) by day 90. Clinical secondary outcomes included tolerability, feasibility, impairment (National Institutes of Health Stroke Scale), grip strength, dependency (modified Rankin Score), disability (Nottingham Extended Activities of Daily Living and Barthel Index), cognition (MiniMental State Examination), and mood (Zung depression score); measurements were made at days 10 and 90. All of the assessments were blinded to treatment assignment. The Data Monitoring Committee assessed unblinded safety data after recruiting 20 and 40 patients into the trial.
Laboratory Measures
Peripheral blood CD34 ϩ cell count was measured at day 5 using flow cytometry (FACScalibur, Becton Dickinson, Oxford, UK) and complied with International Society for Hematotherapy and Graft Engineering guidelines. 11 Full blood counts and putative markers of neuroprotection efficacy (D-dimer, B-natriuretic peptide, matrix metalloproteinase 9, and protein S-100␤; Triage Stroke Panel, Biosite Inc, San Diego, CA) were assessed on days 0, 5, and 10.
Volumetric Analysis
MRI of the brain was performed at baseline and day 90 (Ϯ7) in patients with ischemic stroke, except in those who were intolerant, had contraindications to MRI, or refused imaging. The volume in acutely cerebral infarcted tissue was calculated at baseline based on diffusion-weighted imaging hyperintense lesion outlines at day 0 and at day 90, at which time point intermediately T2-weighted scans were used (online-only, Supplemental Table 2 ). Contralateral ventricular volume on diffusion-weighted images (including the lateral ventricles to the level of the third ventricle) was also assessed as an indirect measure of cerebral atrophy. Two assessors blinded to treatment allocation (T.J.E., M.A.) were trained by an experienced neuroradiologist (D.P.A.) and measured volumes independently.
CD34
؉ Cell Labeling
All of the patients were offered the opportunity to take part in the HSC labeling substudy. For this procedure, 150 mL of blood was collected on day 6 and processed in an HTA licensed clean room. CD34 ϩ cells were immunomagnetically separated from the blood using a CliniMACS Separator (Miltenyi Biotec, Bergisch Gladbach, Germany). The CD34 ϩ antibody used for immunoseparation contained a dextran-coated iron-oxide nanobead, 12 effectively labeling the cells and allowing visualization with gradient echo (T2*-weighted) imaging. 7 After labeling, the CD34 ϩ cells were reinjected intravenously back into the donor patient on the same day and tracked with MR T2* imaging on day 10 (echo time: 16.11 ms; repetition time: shortest; slice thickness: 3 mm). These images are highly sensitive to iron and, therefore, to iron-labeled cells. A neuroradiologist blinded to treatment allocation and cell counts interpreted prelabeling and postlabeling scans.
Statistical Analysis
The primary outcome was the number of participants with Ն1 SAE; this was chosen because G-CSF was associated with a nonsignificant increase in SAEs in our earlier phase IIa trial. 10 The sample size was calculated as 60 assuming ␣5%, power 80%, SAE rate G-CSF 50% versus placebo 20%, ratio G-CSF:placebo 2:1, and losses 5%. Data were analyzed using Fisher exact test, Mann-Whitney U test, repeated-measures ANOVA, or ANCOVA as appropriate. Data are presented as number (percentage), mean (ϮSD), or median (interquartile range). Stroke lesion volume data were positively skewed; it was, therefore, transformed using log(10) to normalize the distribution and antilogged to present the geometric mean. All of the analyses were performed using PASW statistics data editor (version 18.0) and MediStat; analysis was by intention to treat (according to randomization), and statistical significance was taken at PϽ0.05.
Results
Subjects
Of 205 screened participants who were eligible, 60 were included, and the groups (40 G-CSF and 20 placebo) were well matched at baseline (Figure 1 and Table 1 ). The first 
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dose of trial drug was received, on average, 10 days after stroke onset. The mean number of treatment doses received was 4.5 (90.5% in total) in participants randomized to G-CSF and 5.0 (100%) for placebo; 2 participants randomized to G-CSF refused any treatment (but agreed to continued follow-up) before they received their first dose. Other participants stopped treatment after receiving G-CSF because of lower back pain (nϭ1, 2 of 5 doses received), acute illness not related to the trial drug (nϭ1), and administration error (nϭ2, missed doses). One patient withdrew from the trial; although he or she refused follow-up, he or she allowed information on vital status and modified Rankin Score to be obtained from the general practitioner.
Clinical Outcomes
No significant difference in the number of patients with SAE (the primary outcome) or in the mean number of SAEs and adverse events per patient was observed between treatment groups (Table 2 and online-only Supplemental Table 3 ). There were 3 deaths in the G-CSF group (pulmonary embolus, ischemic bowel, and community pneumonia), but all occurred after the end of treatment phase; no deaths occurred in the placebo group. There were no differences in vascular events (nonfatal stroke, nonfatal myocardial infarction, pulmonary embolus, and deep vein thrombosis) or infection rates by day 90 (Table 2) . Fifteen percent (6 G-CSF and 3 placebo) of the participants were included with a primary intracerebral hemorrhage, and no safety concerns were present in this subgroup (online-only Supplemental Table 3 ). No significant difference emerged between treatment and placebo groups with respect to measurements of dependency (modified Rankin Score), disability (Barthel Index and Nottingham Extended Activities of Daily Living), impairment (National Institutes of Health Stroke Scale, Motoricity Index, and grip strength), cognition (Mini-Mental State Examination), or mood (Zung depression score; Table 2 ). When modified Rankin Score is dichotomized (poor outcome Ͼ2), no difference is observed between groups (G-CSF 28 of 40 versus placebo 14 of 20; Pϭ1.0).
Volumetric Analysis
Stroke lesion volumes at baseline and day 90 were analyzed in 20 participants (14 G-CSF and 6 placebo; Table 2 ). Scans were not indicated in 9 recruits (primary hemorrhage) and not performed because of patient refusal (nϭ17), contraindication (nϭ4), scan intolerance (nϭ1), and severe illness or death (nϭ5). Four scans were not analyzable (eg, because of poor quality or the acute lesion becoming embedded in chronic ischemic change). Stroke lesion territory and size varied considerably, but there was no significant difference in baseline diffusion-weighted imaging lesion volume (Table 2) . When adjusted for baseline diffusion-weighted imaging lesion volume, a trend toward reduced lesion volume at day 90 was present in G-CSF-treated patients (ANCOVA, Pϭ0.06). With respect to change in ventricular volume over 90 days, no significant difference was seen between groups (Table 2) .
Laboratory Measures
In comparison with placebo, G-CSF significantly elevated CD34 ϩ cell count (peak: 31.4 versus 3.3 cells per microliter), white cell count (peak: 40.2ϫ10 9 versus 9.5ϫ10 9 cells per liter), and white cell components, including neutrophils (peak: 34.1ϫ10 9 versus 6.9ϫ10 9 cells per liter), at day 5 (online-only Supplemental Table 4 and Figure 2) . By day 10, the counts were returning to normal. There were apparent absolute differences between groups in baseline values in B-natriuretic peptide and D-dimer, but they did not reach statistical significance (Pϭ0.08 and 0.07, respectively). Change in hemoglobin, platelet count, red cell count, hemat- ocrit, D-dimer, B-natriuretic peptide, matrix metalloproteinase 9, and protein S100-␤ did not differ significantly between the treatment groups.
CD34 ؉ Cell Labeling
A phantom model was used to demonstrate that iron-oxide microbead-labeled CD34 ϩ cells (harvested from a volunteer) dispersed in 0.5% agar (4ϫ10 3 cells per mL) were visible on 3T T2* magnetic resonance scanning. Agar alone and unlabeled CD34 cells were not detectable (Figure 3) .
Eight participants (G-CSF 6 and placebo 2) with an ischemic event underwent CD34 ϩ cell labeling. There was marked variation in each participant's response to G-CSF; after 5 days of treatment, between 50 and 430ϫ10 4 cells were harvested from 150 mL of whole blood. Participants receiving placebo yielded between 2 and 7ϫ10 4 CD34 ϩ cells. Labeled cells were then introduced intravenously on day 6. One G-CSF-treated participant developed a hypodensity compatible with iron deposition within his or her left gangliocapsular infarct that was evident on both day 10 and 90 T2* scans (Figure 3 ). The hypodensity was not present at baseline, and this participant received the highest number (430ϫ10 4 ) of labeled CD34 ϩ cells with administration 14 days after stroke onset. Three participants (G-CSF 2 and placebo 1) had evidence of hypodensities compatible with hemorrhagic transformation at days 0, 10, and 90 (T2*-weighted images). The remaining 4 participants receiving labeled cells had no hypodensities in their infarct zones at any time point.
Discussion
The Stem Cell Trial of Recovery Enhancement After Stroke 2 was designed to test the safety of G-CSF and explore mechanisms by which it might work in participants with subacute stroke. There were no significant differences in SAEs (primary outcome) between 2 well-matched groups, supporting that treatment with G-CSF is safe. The inclusion of 9 hemorrhagic strokes also provides initial safety data, although further phase II trials designed specifically in this subgroup are warranted. The majority of subcutaneous injections were received suggesting that the treatment is also feasible to administer, at least when given subacutely. Adverse events experienced that were probably or definitely related to the study drug were typical expected adverse effects of G-CSF (musculoskeletal pain and dizziness, see online-only Supplemental Table 3 ). Despite significant increases in white cell count, no difference in the frequency of vascular events (arterial and venous) or infection was seen. Two of 3 deaths in the G-CSF group were vascular in nature and did not appear to be secondary to active treatment; the overall vascular event rates were identical in each group (15%).
A secondary aim of the trial was designed to establish whether G-CSF mobilized iron-labeled CD34 ϩ cells migrate to the site of the stroke lesion and, therefore, contribute to neurorepair, as seen experimentally. 13 The complexity of recovering, labeling, and readministering CD34
ϩ cells meant that we only studied 8 participants. Of these, T2* MRI suggested the presence of migrated-labeled cells in 1 participant, as demonstrated by new signal loss within the infarct on days 10 (4 days after reinjection) *Data were adjusted for baseline volume (ANCOVA). †Data include deep vein thrombosis and pulmonary embolism. ‡One participant had both urinary tract and lower respiratory tract infections. §Patient had clostridium difficile diarrhea. ¶Dysphasic participants who were unable to answer questions were excluded.
Data show geometric means and SDs.
and 90 and without evidence of baseline hemorrhagic transformation (at day 14 after stroke). This followed intravenous injection of 430ϫ10 4 -labeled CD34 ϩ cells (the highest number recovered from any participant). There was no evidence of T2* signal loss in 4 participants, and baseline hemorrhagic transformation occurred in 3. Bone marrow-derived stem cells have been tracked successfully in animal models of stroke using extracellular and intracellular iron labels, 7,14 a method that confers visibility on gradient echo MRI. Nevertheless, qualitative interpretation of T2* images was limited by scan quality and preexisting signal loss (eg, because of hemosiderin deposition from previous bleeds). New petechial or parenchymal bleeding from hemorrhagic transformation further limited specificity of interpretation of new signal loss. Future mechanistic celllabeling trials should exclude patients with any degree of baseline hemorrhage and consider further the dose of cells administered an alternative route (eg, intra-arterial) and using an intracellular cell label. 15 Although no significant differences between groups were seen with respect to functional outcome (and the trial was not powered to detect this), a trend toward improvement was observed in change in the National Institutes of Health Stroke Scale over 90 days in G-CSF-treated subjects. This is consistent with other measured clinical parameters (Motoricity Index, grip strength, and Nottingham Extended Activities of Daily Living), whereby the mean value in the G-CSF group was nonsignificantly better when compared with placebo. Further phase III trials are, therefore, required to test efficacy. Similarly, a trend to reduced stroke lesion volume and growth in the G-CSF group was observed. This is unexpected considering that G-CSF administration in the subacute phase is aimed to improve outcome via promotion of neurogenesis 4 and angiogenesis 5 and not through neuroprotection. This should be interpreted with caution because of the small sample size and heterogeneity of case mix, although this was accounted for, in part, by adjusting for baseline stroke volume. In addition, preclinical concern on the effects of G-CSF on cerebral atrophy 16 was not demonstrated here; subgroup analysis revealed no significant difference between groups in change in contralateral ventricular volume, although the numbers are small and 90 days may be an insufficient follow-up period.
Altogether, 4 trials have evaluated G-CSF in ischemic stroke, this and the first Stem Cell Trial of Recovery Enhancement After Stroke, as well as 2 others. 17, 18 Of these, the first assessed 10 patients (7 in the G-CSF arm dosed at 15 g/kg OD for 5 days, 3 in the control arm) randomized within 7 days of ictus and no safety concerns were raised. 17 In the Treatment with AX200 for Acute Ischemic Stroke Trial (nϭ44), where treatment was instituted with 12 hours of stroke onset at a cumulative dose range of 30 to 180 g/kg, 18 there was no significant difference between treatment groups with respect to SAEs and thromboembolic complications. Although G-CSF transiently increases total white cell count, therefore potentially leading to vascular complications, there is currently no evidence to suggest that G-CSF causes thromboembolic events or aggravates stroke symptoms. 19 All 4 of the trials were too small individually to assess the effect of G-CSF on functional outcome; when data from the 4 trials are aggregated, no safety concern is obvious with G-CSF (odds ratio: 1.11 [95% CI: 0.38 -3.25]; Figure 4 ). In light of the above evidence and a recent negative trial assessing administration of erythropoietin (another colonystimulating factor 20 ) within 6 hours of ischemic stroke, 21 further phase II/III trials are required evaluating the safety and efficacy of G-CSF.
In summary, this randomized, double-blind, placebocontrolled trial suggests that G-CSF is safe when administered subacutely. It is feasible to label and readminister iron-labeled CD34 ϩ cells in patients with ischemic stroke. Figure 4 . Meta-analysis of the effect of granulocyte-colony stimulating factor on functional outcome events assessed as dependency (modified Rankin score Ͼ2 or Barthel index Ͻ60). 
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